Chromaderm

Chromaderm is a specialized dermatology clinic in Australia, focusing on medical, surgical, and cosmetic services tailored for individuals with pigment issues and skin of color. Founded in 2017, Chromaderm operates from Melbourne, Australia, providing targeted dermatological services. The company was acquired by DermBiont, Inc. in December 2021, which aims to enhance its topical formulation development.

The founder's history is not publicly detailed, and there are no known subsidiaries or parent companies. Chroma Dermatology offers a wide range of medical, surgical, and cosmetic services designed for patients with pigment problems and skin of color. This includes treatments for acne, eczema, hyperhidrosis, and skin cancer, along with cosmetic procedures like chemical peels and laser treatments. The clinic emphasizes personalized care and culturally sensitive skin assessments to cater to diverse populations, particularly in urban areas of Australia.

Chromaderm generates revenue through a B2C model, charging patients for consultations, medical treatments, and cosmetic procedures. Services are billed on a fee-for-service basis, allowing for flexible pricing depending on the nature of the treatment. This includes individual sessions for consultations and various cosmetic procedures, enabling tailored treatment plans for patients. Following the acquisition by DermBiont, Inc.

in December 2021, Chromaderm is positioned to accelerate the development of its topical formulation of Ruboxistaurin. The strategic focus will be on expanding its offerings and capabilities. Specific market expansion plans or upcoming product launches have not been detailed.